Paris, Novembre 24th, 2021
4Living Biotech and Sanofi have recently signed a collaboration agreement aiming at establishing the potential clinical efficacy of Mozobil® as a curative treatment for acute and chronic complications related to COVID-19.
4Living Biotech, a biotechnology company and subsidiary of 4P-Pharma, is the sponsor of the 150-patient Phase 2 international clinical trial. This clinical trial is scheduled for the first quarter of 2022.
This trial follows recent studies showing that the expression of the CXCR4 receptor by neutrophils and lymphocytes significantly correlates with the severity and morbidity of patients with COVID-19. 4Living Biotech and its partners have demonstrated the efficacy of Mozobil® in blocking this receptor to improve the pulmonary pathophysiology associated with respiratory viral infection.
Jean-Marie Job, Francine Le Péchon-Joubert, Partners, and Lionel Attal, Associate Senior-counsel advised 4Living Biotech on this transaction.
“We are delighted to support 4Living Biotech in its collaboration with Sanofi. In the context of the fifth pandemic wave, this transaction and clinical trial show that ingenuity and innovation contribute to the fight against COVID-19 for the benefit of patients“, explains Jérôme Labrousse, Partner at De Gaulle Fleurance et Associés.